Tuesday, November 06, 2018 
Suven Life Sciences Ltd., announces that the grant of one (1) product patent from Israel (255994) and one (1) product patent from Japan (6397131) corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2036 and 2034 respectively.
The granted claims of the patents include the class of selective M1 PAM and 5-HT4 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia etc.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.
Source: Company Press Release
Key Facts
Intellectual Property
This alternative medicine focuses on manual therapy to treat the cialis tab condition. In the viagra in italy end, all events link to one another by a matter of degrees. The magic cipla generic viagra YES mantra is instantly effective at shifting your overall attitude and feelings about life, yet the best side effect of all is it naturally increases your manifesting abilities. The massaging of the oil increases the blood supply and cures viagra super store the impotence or erectile dysfunction.
Suven Life Sciences Ltd
Asia-Pacific > India
Middle East and Africa > Israel
Asia-Pacific > Japan